Science News

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. “In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le...

BASEL, Switzerland--(BUSINESS WIRE)--TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Pasi A. Jänne, M.D., PhD, a world renowned translational thoracic medical oncologist, to its Scientific Advisory Board (SAB). Professor Jänne is one of the global leaders in the treatment of drug-resistant lung cancer and will be an important contributor to further TOLREMO’s goal of preventing non-genetic cancer drug resistance. The company’s lead candidate, TT125-802, is a novel small mole...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025, taking place in Chicago, IL, from March 29-31, 2025. Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for the treatment of adult pati...

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio’s advanced drug screening platform to identify and develop promising therapeutic candidates for FSHD, a debilitating muscular disorder af...

GENEVA--(BUSINESS WIRE)--The WHO Foundation and the L’Oréal Groupe, spearheaded by its Dermatological Beauty Division, are set to launch a four-year partnership to expand access to the treatment of skin conditions worldwide. With a focus on low- and middle-income settings, the partnership will accelerate the World Health Organization’s (WHO’s) efforts to support countries to address skin conditions such as those caused by neglected tropical diseases (NTDs), those exacerbated by climate change a...

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference...

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions (NYSE: ULS) today announced that LG Display’s organic light-emitting diode (OLED) televisions and monitors have achieved UL Solutions Eyesafe Verification, a global first, confirming the accuracy and reliability of LG Display’s marketing claims that their OLED models effectively reduce circadian-stimulating blue light emissions. “UL Solutions’ Marketing Claim Verification process is designed to give consumers confidence in product claims,” said To...

SYDNEY--(BUSINESS WIRE)--Novotech Named Best Contract Research Organization (CRO) in Australia at Asia-Pacific Biopharma Excellence Awards 2025...

CORVALLIS, Ore.--(BUSINESS WIRE)--NuScale Power Corporation announced the opening of the next Energy Exploration (E2) Center™ at Rensselaer Polytechnic Institute (RPI) in Troy, N.Y....

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the "Options"), with an effective grant date of March 24, 2025. The Options have an exercise price e...